An open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 3 years, in children and adolescents with clinically significant fibrosing Interstitial Lung Disease (InPedILD®-ON)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515743-27-00

Acronym

1199-0378

Enrollment

Registered

2024-09-02

Start date

2022-04-04

Completion date

2025-08-05

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Interstitial Lung Disease

Brief summary

The primary endpoint is the incidence of treatment emergent adverse events over the whole trial.

Interventions

DRUGnintedanib

DRUGNintedanib

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the incidence of treatment emergent adverse events over the whole trial.	—

Countries

Belgium, Czechia, France, Greece, Italy, Norway, Poland, Portugal

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026